Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study - Takeaways - MDSpire

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  • By

  • Daniele Noviello

  • María Chaparro

  • Chiara Viganò

  • Andreas Blesl

  • Brigida Barberio

  • Henit Yanai

  • Ambrogio Orlando

  • Rocío Ferreiro-Iglesias

  • Cristina Bezzio

  • Alessandra Zilli

  • Tamás Molnár

  • Cristian Gheorghe

  • Francesco Conforti

  • Tommaso Innocenti

  • Simone Saibeni

  • Peter Bossuyt

  • Raquel Oliveira

  • Anna Maria Carvalhas Gabrielli

  • Alessandra Losco

  • Sophie Vieujean

  • Enrico Tettoni

  • Lorena Pirola

  • Silvia Calderone

  • Maya Kornowski Cohen

  • Gabriele Dragoni

  • Timo Rath

  • Manuel Barreiro-de Acosta

  • Edoardo Vincenzo Savarino

  • Javier P Gisbert

  • Maurizio Vecchi

  • Raja Atreya

  • Flavio Caprioli

  • April 1, 2025

  • 0 min

Share

  • 1

    Fidaxomicin demonstrated a 10% CDI recurrence rate at 8 weeks and an 82% sustained response rate at 12 weeks in IBD patients.

  • 2

    Patients experiencing their first CDI episode had a lower recurrence rate (4.3%) compared to those with previous episodes (16%).

  • 3

    IBD therapy escalation was required in 48% of patients, with a numerically lower need in those achieving sustained response within 30 days.

  • 4

    Five patients with ulcerative colitis underwent colectomy, and one death unrelated to CDI or IBD was reported.

  • 5

    Fidaxomicin was found to be effective and safe for treating CDI in IBD patients, particularly benefiting those who were CDI-naïve.

Original Source(s)

Fidaxomicin for Clostridioides difficile infection in patients with inflammatory bowel disease: a multicenter retrospective cohort study

  • by Daniele Noviello, María Chaparro, Chiara Viganò, Andreas Blesl, Brigida Barberio, Henit Yanai, Ambrogio Orlando, Rocío Ferreiro-Iglesias, Cristina Bezzio, Alessandra Zilli, Tamás Molnár, Cristian Gheorghe, Francesco Conforti, Tommaso Innocenti, Simone Saibeni, Peter Bossuyt, Raquel Oliveira, Anna Maria Carvalhas Gabrielli, Alessandra Losco, Sophie Vieujean, Enrico Tettoni, Lorena Pirola, Silvia Calderone, Maya Kornowski Cohen, Gabriele Dragoni, Timo Rath, Manuel Barreiro-de Acosta, Edoardo Vincenzo Savarino, Javier P Gisbert, Maurizio Vecchi, Raja Atreya, Flavio Caprioli

  • April 1, 2025

Related Content

The innovation trap: How pharma weaponizes a word to extend monopolies

Exploring Comorbidity Patterns in Inflammatory Bowel Disease: Insights from the All of Us Research Program

Combo Therapy for Psoriasis With Obesity

A phase 3b trial tests ixekizumab plus tirzepatide in adults with moderate-to-severe plaque psoriasis and obesity or overweight.